Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 12/20 | 0.53 |
| ▸ | RARB | P10826 | 11/20 | 0.51 |
| ▸ | RARG | P13631 | 10/20 | 0.51 |
| ▸ | RXRB | P28702 | 2/20 | 0.51 |
| ▸ | RXRG | P48443 | 2/20 | 0.51 |
| ▸ | RARA | P10276 | 9/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18287650 | 0.85 | RXRA (0.53) | RXRARARBRARGRXRBRXRG | |
| SCHEMBL8551049 | 0.83 | CSNK2A2 (0.52) | RXRARARBRARGRXRBRXRG | |
| SCHEMBL8553327 | 0.78 | TNKS (0.57) | RXRARARBRARGRXRBRXRG | |
| SCHEMBL9866561 | 0.73 | RARB (0.61) | RXRARARBRARGRXRBRXRG | |
| SCHEMBL9866286 | 0.72 | RARB (0.55) | RXRARARBRARGRXRBRXRG | |
| Hydrochloric Acid SCHEMBL9868032 | 0.71 | RARB (0.54) | RXRARARBRARGRXRBRXRG | |
| SCHEMBL9836023 | 0.71 | MAPT (0.52) | ABCB1 | |
| SCHEMBL7647113 | 0.70 | ABCB1 (0.69) | RXRARARBRARGRXRBRXRG | |
| SCHEMBL1072953 | 0.70 | RXRA (1.00) | RXRARARBRARGRXRBRXRG | |
| SCHEMBL7949665 | 0.69 | RARB (0.67) | RXRARARBRARGRXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230042181-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2023-02-09 | — | — | US | disclosed |
| US-20210285059-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | SYROS PHARMACEUTICALS, INC. | 2021-09-16 | — | — | US | disclosed |
| US-11053552-B2 | Methods of stratifying patients for treatment with retinoic acid receptor-α agonists | SYROS PHARMACEUTICALS, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-10697025-B2 | Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists | SYROS PHARMACEUTICALS, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190249259-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2019-08-15 | — | — | US | disclosed |
| US-10240210-B2 | Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists | SYROS PHARMACEUTICALS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-10167518-B2 | Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists | SYROS PHARMACEUTICALS, INC. (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180187271-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-07-05 | — | — | US | disclosed |
| US-20180187271-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-07-05 | — | — | US | disclosed |
| US-20180155796-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-06-07 | — | — | US | disclosed |
| US-20180155796-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-06-07 | — | — | US | disclosed |
| US-9868994-B2 | Methods of stratifying patients for treatment with retinoic acid receptor-α agonists | SYROS PHARMACEUTICALS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868994-B2 | Methods of stratifying patients for treatment with retinoic acid receptor-α agonists | SYROS PHARMACEUTICALS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9845508-B2 | Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists | SYROS PHARMACEUTICALS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-9845508-B2 | Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists | SYROS PHARMACEUTICALS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20170292165-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-10-12 | — | — | US | disclosed |
| WO-2017177167-A1 | RARA AGONISTS FOR THE TREATMENT OF AML AND MDS | SYROS PHARMACEUTICALS, INC. (US) | 2017-10-12 | — | — | WO | disclosed |
| US-20170292165-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-10-12 | — | — | US | disclosed |
| US-20160355888-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2016-12-08 | — | — | US | disclosed |
| US-20160355888-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2016-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210285059-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | RARA, RARG, RARB | RXRA 4/4885RARB 3/4885RARG 2/4885 |
| US-20180155796-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | RARA, RARG, RARB | RXRA 4/4885RARB 3/4885RARG 2/4885 |
| US-20180187271-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | RARA, RARG, RARB | RXRA 4/4885RARB 3/4885RARG 2/4885 |
| US-10240210-B2 | Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists | RARA, RARG, RARB | RXRA 4/4885RARB 3/4885RARG 2/4885 |
| US-10697025-B2 | Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists | RARA, RARG, RARB | RXRA 4/4885RARB 3/4885RARG 2/4885 |
| US-10167518-B2 | Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists | RARA, RARG, RARB | RXRA 4/4885RARB 3/4885RARG 2/4885 |
| US-20190249259-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | RARA, RARG, RARB | RXRA 4/4885RARB 3/4885RARG 2/4885 |
| US-11053552-B2 | Methods of stratifying patients for treatment with retinoic acid receptor-α agonists | RARA, RARB, RARG | RXRA 4/4885RARB 2/4885RARG 3/4885 |
| US-20160355888-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | RARA, RARG, RARB | RXRA 4/4885RARB 3/4885RARG 2/4885 |
| US-20170292165-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | RARA, RARG, RARB | RXRA 4/4885RARB 3/4885RARG 2/4885 |
| US-20230042181-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | RARA, RARG, RARB | RXRA 4/4885RARB 3/4885RARG 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.